{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-25-000060","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.495505+00:00","generated_at":"2026-05-17T14:34:51.074704+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Caribou Q2 net loss $54.1M ($0.58/sh); clinical data on track for H2 2025","bullets":["GAAP net loss $54.1M ($0.58/sh) vs $37.7M ($0.42/sh) in Q2 2024; non-GAAP loss $32.8M ($0.35/sh) excluding $21.3M impairment.","Cash $183.9M as of June 30, down from $249.4M at Dec 31; expected to fund operations into H2 2027.","Completed enrollment of 20-patient confirmatory cohort for CB-010 in 2L LBCL; data and pivotal trial plans expected H2 2025.","Completed dose escalation enrollment for CB-011 CaMMouflage trial in r/r MM; dose expansion data expected H2 2025.","R&D expenses fell to $27.7M from $35.5M due to pipeline prioritization and workforce reduction; G&A down to $10.4M."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-25-000060","json":"https://secwatch.observer/filing/0001619856-25-000060.json","markdown":"https://secwatch.observer/filing/0001619856-25-000060.md","text":"https://secwatch.observer/filing/0001619856-25-000060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985625000060/0001619856-25-000060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985625000060/crbu-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:34:51.074704+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}